| Jul 16 |
Lisata Therapeutics Announces Completion of Enrollment in its Phase 2a BOLSTER Trial of Certepetide in First-Line Cholangiocarcinoma
|
| Jul 10 |
Lisata Therapeutics’ Certepetide Shows Promise in Improving Standard Treatment for Intrahepatic Cholangiocarcinoma in a Preclinical Model
|
| Jun 14 |
Lisata Therapeutics Hits Enrollment Milestone for Pancreatic Cancer Trial
|
| Jun 13 |
Lisata Therapeutics Announces Full Enrollment of Pancreatic Cancer Cohort of CENDIFOX Trial
|
| May 28 |
Lisata Therapeutics to Participate in Upcoming June 2024 Industry and Investor Events
|
| May 20 |
Sector Update: Health Care Stocks Softer Late Afternoon
|
| May 20 |
Lisata Therapeutics Receives Paediatric Investigation Plan Waiver from the European Medicines Agency for Certepetide in Pancreatic Cancer
|
| May 10 |
Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2024 Earnings Call Transcript
|
| May 10 |
Q1 2024 Lisata Therapeutics Inc Earnings Call
|
| May 10 |
Lisata Therapeutics, Inc. (LSTA) Q1 2024 Earnings Call Transcript
|
